Exelixis: The FDA Delay Costs Less Than The Market Thinks

Sam Mancini 99 Followers Follow Summary The FDA extended its review of Exelixis' zanzalintinib by three months, but no new clinical failure or safety signal was disclosed. At a 10% discount rate, three months reduces an asset's present value by only 2.35%, far less than Exelixis initially lost. CABOMETYX continues growing, and 2026 guidance includes no zanzalintinib launch revenue. At $56.55, Exelixis trades near 16.2 times my 2026 adjusted EPS estimate. I rate it Buy with a $68 target. Hinterhaus Productions/DigitalVision via Getty Images I do not like seeing the words "major amendment " in an FDA filing. They can describe a manageable request for more information, but they can also be the first public sign that a review is becoming This article was written by Sam Mancini 99 Followers Follow Hey this is Sam, an independent investor with a degree in Finance from the University of Oklahoma. I have been investing my own money for several years, with a focus on finding companies that may be overlooked, misunderstood, or valued too conservatively by the market.I am most interested in small and mid sized companies with strong growth potential, especially within technology, artificial intelligence, financial technology, aerospace, and digital infrastructure. I am drawn to businesses operating in growing markets. I also look outside these areas when I find a company with a compelling valuation or an overlooked catalyst.My investing approach combines fundamental research with valuation, market sentiment, and technical analysis. I review financial statements, earnings reports, investor presentations, management commentary, industry trends, and competitive positioning before forming a thesis. I pay particular attention to revenue growth, margins, balance sheet strength, dilution risk, and whether current expectations already appear reflected in the share price.I write independently and am not affiliated with an investment firm. I joined Seeking Alpha to share research on companies that I believe deserve a closer look. My goal is to present a clear investment case, explain what could drive the stock higher, and address the risks that could prove the thesis wrong. Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.